Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status



      Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS). Our hypothesis is that genetic factors contribute to the variability of lipid response to fenofibrate differently in subjects with MetS and without MetS.


      We investigated the association in 25 candidate genes with lipid responses to a 3-weeks trial on fenofibrate in subjects with and without MetS. We employed growth curve mixed models to generate the response phenotypes to fenofibrate in TG, HDL-C, and low-density lipoprotein-cholesterol (LDL-C) and examined the genetic associations accounting for family dependencies.


      After correcting for multiple testing (p < 0.05) and accounting for significant differences in the association effect sizes between subjects with and without MetS (p < 0.05), variants of APOA5 (rs662799) and APOE (rs429358) were associated with HDL-C and LDL-C responses in MetS subjects, while APOA4 (rs675) was associated with TG response in non-MetS subjects. There was also suggestive evidence that MetS may interact with APOA4 (p = 0.017), APOA5 (p = 0.06), and APOE (p = 0.09) to the variation to lipid responses.


      Genetic effects that contributed to the variability of lipid responses to fenofibrate may differ in subjects with and without MetS. This research may provide guidance for more personalized and effective therapies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mathieu P.
        • Pibarot P.
        • Després J.P.
        Metabolic syndrome: the danger signal in atherosclerosis.
        Vasc Health Risk Manage. 2006; 2: 285-302
        • Keating G.M.
        • Croom K.F.
        Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
        Drugs. 2007; 67: 121-153
        • Steiner G.
        How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
        Cardiovasc Drugs Ther. 2009; 23: 403-408
        • Scott R.
        • O’Brien R.
        • Fulcher G.
        • et al.
        Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
        Diabetes Care. 2009; 32: 493-498
        • Barter P.J.
        • Rye K.A.
        Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?.
        Arterioscler Thromb Vasc Biol. 2008; 28: 39-46
        • Athyros V.G.
        • Mikhailidis D.P.
        • Papageorgiou A.A.
        • et al.
        Targeting vascular risk in patients with metabolic syndrome but without diabetes.
        Metabolism. 2005; 54: 1065-1074
        • Lai C.Q.
        • Arnett D.K.
        • Corella D.
        • et al.
        Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
        Arterioscler Thromb Vasc Biol. 2007; 27: 1417-1425
        • Ruan X.
        • Zheng F.
        • Guan Y.
        PPARs and the kidney in metabolic syndrome.
        Am J Physiol Renal Physiol. 2008; 294: F1032-F1047
        • Pollex R.L.
        • Hegele R.A.
        Genetic determinants of the metabolic syndrome.
        Nat Clin Pract Cardiovasc Med. 2006; 3: 482-489
        • Dallongeville J.
        • Cottel D.
        • Wagner A.
        • et al.
        The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides.
        BMC Med Genet. 2008; 9: 84
        • Higgins M.
        • Province M.
        • Heiss G.
        • et al.
        NHLBI Family Heart Study: objectives and design.
        Am J Epidemiol. 1996; 143: 1219-1228
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
        Circulation. 2005; 112: 2735-2752
        • Smith J.A.
        • Arnett D.K.
        • Kelly R.J.
        • et al.
        The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
        Eur J Hum Genet. 2008; 16: 603-613
        • Benjamini Y.
        • Hochberg Y.
        Controlling the false discovery rate: a practical and powerful approach to multiple testing.
        J Royal Stat Soc. 1995; 85: 289-300
        • Srivastava R.A.
        • Jahagirdar R.
        • Azhar S.
        • Sharma S.
        • Bisgaier C.L.
        Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
        Mol Cell Biochem. 2006; 285: 35-50
        • Talmud P.J.
        • Hawe E.
        • Martin S.
        • et al.
        Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.
        Hum Mol Genet. 2002; 11: 3039-3046
        • Liu Y.
        • Ordovas J.M.
        • Gao G.
        • et al.
        Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
        Pharmacogenet Genomics. 2009; 19: 161-169
        • Grallert H.
        • Sedlmeier E.M.
        • Huth C.
        • et al.
        APOA5 variants and metabolic syndrome in Caucasians.
        J Lipid Res. 2007; 48: 2614-2621
        • Niculescu L.S.
        • Fruchart-Najib J.
        • Fruchart J.C.
        • Sima A.
        Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome.
        Clin Chem Lab Med. 2007; 45: 1133-1139
        • Komurcu-Bayrak E.
        • Onat A.
        • Poda M.
        • et al.
        Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T > C and c.56C > G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.
        Clin Chem Lab Med. 2008; 46: 778-784
        • Kisfali P.
        • Mohás M.
        • Maasz A.
        • et al.
        Apolipoprotein A5 IVS3 + 476A allelic variant associates with increased triglyceride levels and confers risk for development of metabolic syndrome in Hungarians.
        Circ J. 2008; 72: 40-43
        • Hsu L.A.
        • Ko Y.L.
        • Chang C.J.
        • Teng M.S.
        • Wu S.
        • Hu C.F.
        Apolipoprotein A5 gene −1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan.
        Clin Chem Lab Med. 2008; 46: 1714-1719
        • Yamada Y.
        • Ichihara S.
        • Kato K.
        • et al.
        Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people.
        J Med Genet. 2008; 45: 22-28
        • Huang X.S.
        • Zhao S.P.
        • Zhang Q.
        • Bai L.
        • Hu M.
        Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome.
        Atherosclerosis. 2009; 204: e99-e102
        • Cardona F.
        • Guardiola M.
        • Queipo-Ortuño M.I.
        • Murri M.
        • Ribalta J.
        • Tinahones F.J.
        The −1131T > C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.
        Atherosclerosis. 2009; 206: 148-152
        • Irvin M.R.
        • Kabagambe E.K.
        • Tiwari H.K.
        • et al.
        Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.
        Circ Cardiovasc Genet. 2010; 3: 462-467
        • Christidis D.S.
        • Liberopoulos E.N.
        • Kakafika A.I.
        • et al.
        The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
        J Cardiovasc Pharmacol Ther. 2006; 11: 211-221
        • Brisson D.
        • Ledoux K.
        • Bosse Y.
        • et al.
        Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
        Pharmacogenetics. 2002; 12: 313-320
        • Foucher C.
        • Rattier S.
        • Flavell D.M.
        • et al.
        Response to micronized fenofibrate treatment is associated with the peroxisomeproliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
        Pharmacogenetics. 2004; 14: 823-829
        • Sima A.
        • Iordan A.
        • Stancu C.
        Apolipoprotein E polymorphism – a risk factor for metabolic syndrome.
        Clin Chem Lab Med. 2007; 45: 1149-1153
        • Sertic J.
        • Juricic L.
        • Ljubic H.
        • et al.
        Variants of ESR1, APOE LPL and IL-6 loci in young healthy subjects: association with lipid status and obesity.
        BMC Res Notes. 2009; 2: 203-207